Lanean...
Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
BACKGROUND: Hypertension (HTN) is a common adverse event of the vascular endothelial growth factor pathway inhibitor apatinib. This study was conducted to evaluate the association of apatinib-induced HTN with clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: We...
Gorde:
| Argitaratua izan da: | Onco Targets Ther |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6362948/ https://ncbi.nlm.nih.gov/pubmed/30774384 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S189984 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|